ApicHope Pharma has submitted the IND application for an oral small molecule GLP-1R agonist APH01727 for patients with type 2 diabetes and obesity in China. ApicHope Pharmaceutical founded by Li Hanxiong engages in the research and development, production, and sales of traditional Chinese medicine products, chemical medicine, and biological vaccines. Li Hanxiong APH01727 In the press release issued by ApicHope, it was stated that APH01727 is intended to be a daily dose small molecule GLP-1 receptor agonist. In 2022, ApicHope filed a patent （WO2024046342） covering the benzo bicyclic compounds aimed at treating GLP-1 receptor agonist-mediated diseases and/or disorders. The patent indicates that compound 4 has an EC 50 value of approximately 0.08 nM, demonstrating significantly higher potency compared to danuglipron, which has an EC50 of around 13 nM. Compounds in the patent Oral GLP-1R Agonists in China Although Pfizer and vTv (Huadong) terminated their oral small molecule GLP-1R a
China Biotech XYZ Shares Updates Related to New Drug Development in China